SCHEMBL1018519

SCHEMBL1018519

COCC(C)Nc1ccc2c(n1)CCN(CC(=O)N1CCN(C3CCC3)CC1)C2

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HCAR3 P49019 1/20 0.36
HRH3 Q9Y5N1 2/20 0.36
CDK4 P11802 10/20 0.35
CDK2 P24941 7/20 0.35
CDK6 Q00534 7/20 0.35
KMT2A Q03164 2/20 0.35
ALDH1A1 P00352 2/20 0.35
TSHR P16473 1/20 0.35
PARP1 P09874 1/20 0.35
KDM4E B2RXH2 3/20 0.34
MEN1 O00255 1/20 0.34
LMNA P02545 1/20 0.34
FLT3 P36888 2/20 0.34
CDK1 P06493 3/20 0.33
CCNB1 P14635 2/20 0.33
CCNE1 P24864 2/20 0.33
ADRA1A P35348 1/20 0.33
CDK7 P50613 2/20 0.33
CDK9 P50750 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1019165 0.91 CDK4 (0.36) HCAR3HRH3CDK4CDK2CDK6
SCHEMBL1014133 0.90 ADRA1A (0.43) HRH3CDK4CDK2CDK6KMT2A
SCHEMBL1017981 0.89 CDK4 (0.35) HRH3CDK4CDK2CDK6ALDH1A1
SCHEMBL1017991 0.88 CDK4 (0.36) HRH3CDK4CDK2CDK6ALDH1A1
SCHEMBL1018492 0.86 ADRA1A (0.43) HCAR3HRH3CDK4CDK2CDK6
SCHEMBL1018763 0.86 ADRA1A (0.38) HRH3CDK4CDK2CDK6ALDH1A1
SCHEMBL1015014 0.85 ADRA1A (0.35) CDK4CDK2CDK6KMT2AALDH1A1
SCHEMBL1016337 0.85 ADRA1A (0.39) HRH3CDK4CDK2CDK6KMT2A
SCHEMBL1016696 0.84 CDK4 (0.36) HRH3CDK4CDK2CDK6ALDH1A1
SCHEMBL1016832 0.83 PARP1 (0.39) HCAR3HRH3CDK4CDK2CDK6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110082130-A1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES LIGAND PHARMACEUTICALS, INC. (US) 2011-04-07 US disclosed
US-20110082130-A1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES LIGAND PHARMACEUTICALS, INC. (US) 2011-04-07 US disclosed
US-20110082130-A1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES LIGAND PHARMACEUTICALS, INC. (US) 2011-04-07 US disclosed
EP-1998620-B1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES NEUROGEN CORP (US) 2011-01-12 EP disclosed
US-7795262-B2 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION (US) 2010-09-14 US disclosed
US-7795262-B2 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION (US) 2010-09-14 US disclosed
US-7795262-B2 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION (US) 2010-09-14 US disclosed
US-20070232591-A1 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION 2007-10-04 US disclosed
US-20070232591-A1 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION 2007-10-04 US disclosed
US-20070232591-A1 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION 2007-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232591-A1 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues HRH3, HRH4, HRH1 HCAR3 10/4885HRH3 1/4885CDK4 2953/4885
US-20110082130-A1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES HRH3, HRH4, HRH1 HCAR3 10/4885HRH3 1/4885CDK4 2953/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.